StockData

Biogen vs Moderna

BIIB and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIIB and MRNA compare

Moderna is the larger company, worth 2.2 times as much as Biogen ($82.6B against $37.1B).

Biogen grew revenue faster over the last twelve months (2.3% versus −27.6% for Moderna).

Biogen keeps more of each dollar of sales as profit, with a net margin of 3.4% compared with −141% at Moderna.

Moderna scores higher on the StockData Score (5 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIIBMRNA
Size and price
Market cap$37.1B$82.6B
Share price$250.79$206.80
Change, 1 year49.7%735%
Change, 5 years3.2%−37.3%
Beta (5Y)0.14−0.29
Employees7,5004,700
StockData Score
Total score45 (better)
Valuation score1 (better)0
Growth score01 (better)
Performance score11
Health score23 (better)
Dividend score00
Valuation
P/E107×–
P/S3.6× (better)37.1×
P/B–12.2×
EV/EBITDA21.9×–
P/FCF17.9×–
FCF yield5.6% (better)−1.5%
Fair value$160.54$32.48
Margin of safety−56.2% (better)−537%
Growth
Revenue growth (TTM)2.3% (better)−27.6%
Revenue growth, 5Y average−6.0%19.3% (better)
Net income growth (TTM)−78.4%–
EPS growth (TTM)−78.7%–
EPS growth, 5Y average−18.7%–
Profitability
Gross margin74.0% (better)23.4%
Operating margin–−149%
Net margin3.4% (better)−141%
FCF margin20.1% (better)−55.8%
Return on equity–−39.0%
Return on invested capital–−80.9%
Financial health
Debt / equity–0.09
Current ratio1.952.29 (better)
Altman Z-score3.0712.01 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions96.2%79.9%
Held by insiders0.21%5.6%
Insider net buying, 12 months−$905K (better)−$81.6M
Superinvestors holding1–
Short interest, % of float3.7%8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.